Freedom of Information

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

• Ipilimumab (monotherapy)
• Nivolumab (monotherapy)
• Nivolumab AND Ipilimumab (combination)
• Pembrolizumab
• Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
• Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?

• Nivolumab (monotherapy)
• Nivolumab + Ipilimumab
• Nivolumab + Cabozantinib
• Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:

• Nivolumab monotherapy or in combination with Ipilimumab
• Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
• Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.